Table 3 Glucocorticoid dose reduction
From: Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
Biologics compared to placebo for the treatment of Systemic Lupus Erythematosus measured by glucocorticoid dose reduction | |||||
|---|---|---|---|---|---|
Patient or population: Systemic Lupus Erythematosus 1. Setting: Inpatients then outpatients Intervention: Biologics Comparison: Standard of care, placebo | |||||
Outcomes | № of participants (studies) Follow-up | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
Risk with placebo | Risk difference with Glucocorticoid dose | ||||
number of patients with prednisone equivalent ≤ 7.5 mg/day, with reduction ≥ 25% from baseline—Belimumab | 2317 (5 RCTs) | ⨁⨁⨁◯ Moderatec,d | RR 1.45 (1.16 to 1.80) | 121 per 1,000 | 54 more per 1,000 (19 more to 97 more) |
number of patients with prednisone equivalent ≤ 7.5 mg/day, with reduction ≥ 25% from baseline—Tabalumab | 999 (2 RCTs) | ⨁◯◯◯ Very lowa,b,d,e | RR 1.21 (0.78 to 1.89) | 144 per 1,000 | 30 more per 1,000 (32 fewer to 128 more) |
number of patients with prednisone equivalent ≤ 10 mg/day—Anifrolumab | 605 (3 RCTs) | ⨁⨁◯◯ Lowa,d,e,f | RR 1.46 (1.16 to 1.84) | 301 per 1,000 | 139 more per 1,000 (48 more to 253 more) |
number of patients with prednisone equivalent ≤ 10 mg/day—Rontalizumab | 235 (1 RCT) | ⨁⨁⨁◯ Moderatea,c,d | RR 1.21 (1.00 to 1.46) | 633 per 1,000 | 133 more per 1,000 (0 fewer to 291 more) |
number of patients with prednisone equivalent ≤ 10 mg/day—Blisibimod | 442 (1 RCT) | ⨁⨁⨁◯ Moderatec,d | RR 1.64 (1.07 to 2.52) | 132 per 1,000 | 84 more per 1,000 (9 more to 201 more) |